B. Riley initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $22 price target The firm says the company “stands out” given its lipid-enabled and unlocked nucleic acid modified RNA platform. The platform enables multi-tissue, safe, efficient, and effective delivery of messenger RNA that is applied to two wholly-owned rare disease programs, inhaled ARCT-032 for cystic fibrosis and intravenously administered ARCT-810 for ornithine transcarbamylase, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Arcturus Therapeutics price target lowered to $21 from $66 at Canaccord
- Regulatory Shifts Cloud Arcturus Therapeutics’ Outlook as FDA Delays KOSTAIVE BLA and Demands New COVID-19 Efficacy Data
- Arcturus Therapeutics Balances Pipeline Progress With Cash Strain
- Arcturus Therapeutics price target lowered to $25 from $72 at Piper Sandler
- Arcturus Therapeutics: Dose Selection and Trial Design Uncertainty Justify Neutral Rating Despite Modestly Higher Target Price